The Ebola outbreak in eastern Congo has now recorded more than 380 confirmed cases and 63 deaths, health minister Roger Kamba told reporters in Kinshasa, as the virus continues to creep across Ituri province and into adjacent regions. An attack on a burial team in South Kivu this week, which forced responders to abandon a coffin and left a highly infectious body to be handled by untrained community members, has underscored how mistrust and insecurity are thwarting containment. Contact tracing has improved to 55 per cent, up from a dire 9 per cent at the start, but remains far below the threshold needed to break chains of transmission.

The outbreak is driven by the Bundibugyo strain of the virus, for which there exist no approved vaccines or treatments — a sobering gap that has frustrated researchers for nearly two decades. Experimental vaccines targeting Bundibugyo have been sitting in freezers in Winnipeg, Canada, and Texas in the United States since at least 2007, with clinical trials never materialising due to lack of funding and institutional inertia. "It has been since 2007–2008 that we have been saying everything should be put in place to do a clinical study," Canadian microbiologist Gary Kobinger lamented. While American medical centres say they stand ready to handle cases, and one US citizen was already treated in Germany, those experimental vials remain a promise frozen in time.

Viewed from regional capitals and global health bodies, the response is assembling the familiar machinery of outbreak control. The East African Community has approved a technical task force and deployed ten mobile laboratories across seven countries to speed testing. Nigeria’s disease control centre has classified the risk of importation as high, pointing to porous borders and population movement, and is pressing state governors for funding. The East African Business Council has warned against knee-jerk trade restrictions, cautioning that supply-chain disruption could compound economic damage without improving public health — a tension familiar to anyone who watched the COVID-19 era play out across the continent.

On the ground in Ituri, the defensive walls are paper-thin. Doctors and midwives in Bunia have fallen ill after treating patients without adequate protective gear, their medical director Elisabeth Furaha telling a visiting reporter: "We live with fear." Even samples taken from symptomatic staff went untested for want of kits. It is in this vacuum that traditional healers such as Kabika, foraging for eucalyptus and papaya leaves, have become the de facto frontline. Their deep community ties can be a bridge for health messaging, officials concede, but their prominence also reflects a profound crisis of confidence in state-led medicine — the same mistrust that prompted villagers to stone the burial team.

The path forward will demand not only accelerated emergency-use authorisation for the Bundibugyo vaccines languishing in cold storage, but also a far more deliberate effort to build local trust. Cross-border cooperation, already being formalised by the EAC, must be balanced against the risk that alarmist measures throttle trade and isolate affected communities further. For now, Congo’s nineteenth Ebola outbreak is a slow-burn trauma, its toll climbing in remote zones where the virus is often several steps ahead of the response.